DDIWAS: High-throughput electronic health record-based screening of drug-drug interactions.
DDIWAS: High-throughput electronic health record-based screening of drug-drug interactions.
复制标题
DDIWAS：基于高通量电子健康记录的药物间相互作用筛查。
DOI：
10.1093/jamia/ocab019
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Wei,Wei-Qi
中科院分区：
文献类型：
--
作者：
Wu,Patrick;Nelson,ScottD;Zhao,Juan;StoneJr,CosbyA;Feng,QiPing;Chen,Qingxia;Larson,EricA;Li,Bingshan;Cox,NancyJ;Stein,CMichael;Phillips,ElizabethJ;Roden,DanM;Denny,JoshuaC;Wei,Wei-Qi
我们开发并评估了药物相互作用广泛关联研究（DDIWAS）。这种新的方法检测潜在的药物相互作用（DDI），利用数据从电子健康记录（EHR）过敏list.Materials和MethodsTo确定潜在的DDI，DDIWAS扫描药物对，经常记录在一起的过敏列表。使用去识别的医疗记录，我们测试了616种药物与辛伐他汀（一种常见的降脂药物）和阿托伐他汀（一种常见的降压药物）的潜在DDI。我们评估了使用现有知识库和领域专家评审重新发现已知DDI的性能。为了验证潜在的新的DDI，我们手动审查患者的图表和检索literature.ResultsDDIWAS复制34个已知的DDI。辛伐他汀和阿托伐他汀检测已知DDI的阳性预测值分别为0.85和0.86。DDIWAS还发现了辛伐他汀-氢氯噻嗪、氨氯地平-奥美拉唑和氨氯地平-伐昔洛韦之间潜在的新型相互作用。一个软件包进行DDIWAS是公开的。ConclusionsIn这个概念验证的研究，我们证明了将现有的过敏清单挖掘的信息，以检测DDI在现实世界的临床环境中的价值。由于过敏清单是在EHR中常规收集的，因此DDIWAS有可能检测和验证机构间的DDI信号。
ObjectiveWe developed and evaluated Drug-Drug Interaction Wide Association Study (DDIWAS). This novel method detects potential drug-drug interactions (DDIs) by leveraging data from the electronic health record (EHR) allergy list.Materials and MethodsTo identify potential DDIs, DDIWAS scans for drug pairs that are frequently documented together on the allergy list. Using deidentified medical records, we tested 616 drugs for potential DDIs with simvastatin (a common lipid-lowering drug) and amlodipine (a common blood-pressure lowering drug). We evaluated the performance to rediscover known DDIs using existing knowledge bases and domain expert review. To validate potential novel DDIs, we manually reviewed patient charts and searched the literature.ResultsDDIWAS replicated 34 known DDIs. The positive predictive value to detect known DDIs was 0.85 and 0.86 for simvastatin and amlodipine, respectively. DDIWAS also discovered potential novel interactions between simvastatin-hydrochlorothiazide, amlodipine-omeprazole, and amlodipine-valacyclovir. A software package to conduct DDIWAS is publicly available.ConclusionsIn this proof-of-concept study, we demonstrate the value of incorporating information mined from existing allergy lists to detect DDIs in a real-world clinical setting. Since allergy lists are routinely collected in EHRs, DDIWAS has the potential to detect and validate DDI signals across institutions.